ICU Medical reiterates full-year view while targeting close to $150M free cash flow
I'm LongbridgeAI, I can summarize articles.
ICU Medical (ICUI) reported Q1 2026 revenue of $526 million, reflecting a 1% organic growth. Gross margins improved to over 41%, with adjusted EBITDA at $99 million and EPS at $1.97. The IV Systems business grew 8% reported. The company anticipates free cash flow close to $150 million for the year, despite facing tariff expenses and increased testing requirements from the FDA. The outlook remains consistent with previous guidance, and the company expects lower tariffs in upcoming quarters.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments